AstraZeneca plc
Oncology Drug Pipeline Analysis – June 2021

Molecule	Target	Phase	Indication	NCT Number	Mol Type
Savolitinib / AZD6094	c-Met	III	Renal Cell Carcinoma	NCT03091192	Small Molecule
		II	Advanced Gastric Adenocarcinoma	NCT02449551
		II	Colorectal Carcinoma	NCT03592641
Capivasertib/ AZD5363	AKT	III	Triple Negative Breast Cancer	NCT03997123	Small Molecule
		II	Advanced Lymphoma	NCT04439123
			Refractory Plasma Cell Myeloma
		I/II	Prostate Cancer	NCT02121639
Adavosertib / AZD1775	WEE1	II	Uterine Serous Carcinoma	NCT04590248	Small Molecule
		II	Advance Fallopian Tube Carcinoma	NCT03579316
			Advance Ovarian Carcinoma
			Advance Primary Peritoneal Carcinoma
		I/II	Recurrent Medulloblastoma	NCT02095132
			Recurrent Neuroblastoma
			Recurrent Rhabdomyosarcoma
AZD2811	Aurora B	II	Small-Cell Lung Cancer	NCT04745689	Small Molecule
		I/II	Acute Myeloid Leukaemia	NCT03217838
Camizestrant / AZD9833	SERD	II	HER2-negative Breast Cancer	NCT04588298	Small Molecule
Imaradenant / AZD4635 /	A2A R	II	Prostate Cancer (mCRPC)	NCT04089553	Small Molecule
		I/II	Non-Small-Cell Lung Cancer	NCT03381274
MEDI0457	-	II	HPV+ Oropharyngeal Squamous Cell Cancer	NCT04001413	Vaccine
		II	Recurrent Anal Canal Carcinoma	NCT03439085
			Recurrent Cervical Carcinoma
			Recurrent Malignant Neoplasm
			Recurrent Penile Carcinoma
			Recurrent Vaginal Carcinoma
		I/II	HPV+ Head and Neck Cancer	NCT03162224
AZD0466	BCL2/xL	I	Advanced Solid Tumors	NCT04214093	Small Molecule
			Lymphoma
			Multiple Myeloma
			Hematologic Malignancies
AZD1390	ATM	I	Glioblastoma	NCT03423628	Small Molecule
AZD4573	CDK9	I	R/R Haematalogical malignancies	NCT03263637	Small Molecule
AZD5305	PARP1Sel	I	Ovarian Cancer	NCT04644068	Small Molecule
			Breast Cancer
			Pancreatic Cancer
			Prostate Cancer
AZD5991	MCL1	I/II	R/R Haematalogical malignancies	NCT03218683	Small Molecule
AZD7648	DNAPK	I/II	Advance Cancer	NCT03907969	Small Molecule
AZD8701	FOXP3	I	Clear Cell Renal Cell Cancer	NCT04504669	Small Molecule
			Non-Small-Cell Lung Cancer
			Triple Negative Breast Neoplasms
			Head and Neck Cancer
			Small Cell Lung Cancer
			Gastric Cancer
			Melanoma
			Cervical Cancer
IPH5201	CD39	I	Advanced Solid Tumors	NCT04261075	Monoclonal Antibody
MEDI2228	BCMA	I	R/R Multiple Myeloma	NCT03489525	Antibody Drug Conjugate
MEDI5395	-	I	Advanced Solid Tumors	NCT03889275	Oncolytic Virus
MEDI9253	-	I	Advanced Solid Tumors	NCT03889275	Oncolytic Virus
MEDI5752	PD-1, CTLA-4	I	Advanced Renal Cell Carcinoma	NCT03530397	Bispecific Antibody
		I	Advance Non-Small Cell Lung Cancer

AstraZeneca Active Oncology Pipeline Drug Description

• Savolitinib (volitinib, AZD6094, HMPL-504) is a potent and selective small molecule MET kinase inhibitor.
• Capivasertib is a novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B).
• Adavosertib/ MK-1775 is a small molecule inhibitor of the tyrosine kinase WEE1; that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex.
• In Sept 2013, Merck out-licensed global development and commercialization rights of MK-1775, a WEE1 inhibitor, to AstraZeneca.
• AZD2811-nanoparticle (np) is a novel, encapsulated slow release AURKB inhibitor.
• Camizestrant / AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD).
• AZD4635 inhibits adenosine 2a receptor (A2aR) signaling and improves immune activation and anti-tumor activity in preclinical models.
• MEDI0457 (previously called INO-3112) is an investigational immunotherapy being developed to treat human papillomavirus (HPV)-positive cervical cancer and head and neck cancer.
• MEDI0457 was originally developed by Inovio, but MedImmune, acquired exclusive rights to the drug in Aug 2015.
• AZD0466, a nanomedicine of a potent dual Bcl-2/Bcl-xL inhibitor, exhibits anti-tumor activity in a range of hematological and solid tumors.
• AZD1390 is a highly potent brain penetrant ATM (Ataxia telangiectasia mutant) kinase inhibitor that blocks ATM-dependent signaling and repair of DNA double strand breaks (DSBs) in the genome.
• AZD4573 Is a highly selective CDK9 Inhibitor that Suppresses MCL-1 and induces Apoptosis in Hematologic Cancer Cells.
• AZD5305 selectively targets and binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway.
• AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, most notably myeloma and acute myeloid leukemia, by activating the Bak-dependent mitochondrial apoptotic pathway.
• AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation and chemotherapy activity.
• AZD8701 is a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer.
• IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway.
• MEDI2228 is a monoclonal antibody that is conjugated to a warhead that is a DNA cross-linking agent pyrrolo benzodiazepine (PBD) through a cleavable linker.
• MEDI5395 is a recombinant Newcastle disease virus incorporating a granulocyte macrophage colony-stimulating factor (GM-CSF) transgene that exhibits tumor cell-specific viral replication, stimulates PD-L1 expression, and induces tumor regression in murine and patient-derived xenograft models.
• MEDI 9253 is a recombinant Newcastle disease virus, encoding interleukin-12 (IL-12), being developed by AstraZeneca, for the treatment of solid tumors.
• MEDI5752 is a monovalent bispecific antibody designed to suppress the PD-1 pathway and provide modulated CTLA-4 inhibition favoring enhanced blockade on PD-1+ activated T cells.